Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 5:00 pm Sale | 2024-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | Satter Muneer A | 5,747,906 2.600% | -10,457,213 (-64.53%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Akebia Therapeutics, Inc. AKBA | BlackRock Inc. BLK | 15,197,207 7.200% | 0 (Unchanged) | Filing History |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | Akebia Therapeutics, Inc. AKBA | BlackRock Inc. BLK | 15,197,207 7.200% | 10,857,181 (+250.16%) | Filing History |
| 2024-02-13 4:58 pm Sale | 2023-12-29 | 13G | Akebia Therapeutics, Inc. AKBA | VANGUARD GROUP INC | 7,607,472 4.040% | -3,631,398 (-32.31%) | Filing History |
| 2024-02-09 4:00 pm Purchase | 2023-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | Satter Muneer A | 16,205,119 8.600% | 1,115,000 (+7.39%) | Filing History |
| 2023-02-10 1:08 pm Purchase | 2022-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | Satter Muneer A | 15,090,119 8.200% | 1,225,789 (+8.84%) | Filing History |
| 2023-02-09 10:54 am Sale | 2022-12-30 | 13G | Akebia Therapeutics, Inc. AKBA | VANGUARD GROUP INC | 11,238,870 6.110% | -7,120,550 (-38.78%) | Filing History |
| 2023-01-20 08:55 am Sale | 2022-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | STATE STREET CORP STT | 571,936 0.310% | -11,171,525 (-95.13%) | Filing History |
| 2022-12-19 4:10 pm Purchase | 2022-12-08 | 13G | Akebia Therapeutics, Inc. AKBA | Satter Muneer A | 13,864,330 7.500% | 10,797,287 (+352.04%) | Filing History |
| 2022-07-08 4:56 pm Sale | 2022-06-30 | 13G | Akebia Therapeutics, Inc. AKBA | BlackRock Inc. BLK | 4,340,026 2.400% | -9,784,189 (-69.27%) | Filing History |
| 2022-06-09 2:15 pm Purchase | 2022-05-31 | 13G | Akebia Therapeutics, Inc. AKBA | VANGUARD GROUP INC | 18,359,420 10.000% | 5,123,751 (+38.71%) | Filing History |
| 2022-02-10 1:23 pm Sale | 2021-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | STATE STREET CORP STT | 11,743,461 6.710% | -2,263,176 (-16.16%) | Filing History |
| 2022-02-09 3:16 pm Purchase | 2021-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | VANGUARD GROUP INC | 13,235,669 7.560% | 4,800,910 (+56.92%) | Filing History |
| 2022-02-07 4:41 pm Purchase | 2021-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | BlackRock Inc. BLK | 14,124,215 8.100% | 2,726,667 (+23.92%) | Filing History |
| 2021-08-10 07:57 am Sale | 2021-07-30 | 13G | Akebia Therapeutics, Inc. AKBA | WELLINGTON MANAGEMENT GROUP LLP | 711 0.000% | -12,589,752 (-99.99%) | Filing History |
| 2021-07-12 10:45 am Sale | 2021-06-30 | 13G | Akebia Therapeutics, Inc. AKBA | STATE STREET CORP STT | 14,006,637 8.750% | -8,469,897 (-37.68%) | Filing History |
| 2021-02-12 06:42 am Purchase | 2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | Nantahala Capital Management LLC | 7,040,487 4.900% | 303,367 (+4.50%) | Filing History |
| 2021-02-11 12:43 pm Sale | 2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | STATE STREET CORP STT | 22,476,534 15.550% | -340,636 (-1.49%) | Filing History |
| 2021-02-10 10:30 am Purchase | 2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | VANGUARD GROUP INC | 8,434,759 5.840% | 8,434,759 (New Position) | Filing History |
| 2021-02-10 10:26 am Purchase | 2021-01-31 | 13G | Akebia Therapeutics, Inc. AKBA | STATE STREET CORP STT | 22,817,170 15.790% | 7,476,699 (+48.74%) | Filing History |